McKesson Corporation vs Under Armour Inc Class A — how do they compare? McKesson Corporation trades at $936.25 (market cap $108.46B), while Under Armour Inc Class A trades at $4.91 (market cap $2.07B). The key difference: McKesson Corporation is far larger — about 52.4× Under Armour Inc Class A's market cap, and McKesson Corporation pays a 0.4% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Under Armour Inc Class A for 99 Days on average.
| MCK | UAA | |
|---|---|---|
Market Cap | $108.46B | $2.07B |
Volume | 712,607 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $8.14 |
52-Week Low | $725.17 | $4.17 |
Typical Hold Time | 74 Days | 99 Days |
Enterprise Value | $115.00B | $3.05B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Under Armour (UAA) trades at $4.82, down 1.23% on the day, with a mixed technical picture showing a bullish overall signal but a neutral RSI. The company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion, though recent quarters have shown some earnings beats. Analyst consensus is a $5.79 price target, but the stock faces headwinds from weak consumer demand and negative cash flow trends.
The outlook is cautious; while cost discipline supports margins, persistent revenue weakness and negative profitability pose significant risks. The stock's low P/S ratio of 0.42 may attract value investors, but sustained operational improvements are needed for a durable recovery amid competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →